GLP-1s could be the product that pushes Hims & Hers over the edge to mainstream adoption.Hims & Hers (HIMS -5.59%) has been a great growth stock since coming public, but it's now starting to turn a profit. In this video, Travis Hoium highlights the company's financials and why the launch of GLP-1 medications could be a game-changer.*Stock prices used were end-of-day prices of May 20, 2024. The video was published on May 21, 2024. ...